Author:
Heinhuis K.M.,Ros W.,Kok M.,Steeghs N.,Beijnen J.H.,Schellens J.H.M.
Reference157 articles.
1. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial;Larkin;J Clin Oncol,2017
2. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
4. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum‐containing chemotherapy;Ning;Oncologist,2017
5. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1;Sul;Oncologist,2016
Cited by
384 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献